Our APPCI model had a significantly better predictive performance compared to the FI, APRI, GPI, and APGPI models, respectively. Conclusions CP levels were negatively and indirectly correlated with inflammation and fibrosis stages in CHB patients. Our model used routine laboratory variables along with CP to accurately predict liver fibrosis in CHB. Disclosures: The following people have nothing to disclose: Da-wu Zeng, Jing Dong, Yu-rui Liu, Yue-Yong Zhu, Su

LIN, Jing Chen, Jia-ji Jiang Background: HBeAg and HBcAg share an identical sequence of 149 amino-acids. Hence, they Galunisertib are collectively called Hepatitis B virus core-related antigens (HBcrAg). HBcrAg levels have been shown to correlate with both HBsAg and HBV DNA in Asian patients infected with HBV genotypes B and C. Moreover HBcrAg but not HBsAg levels were independently associated with the development of HCC in Japanese patients. The aim of this study was to investigate the performance of an HBcrAg assay in European patients mainly infected with HBV genotypes A and D. Methods:

Plasma samples of 302 HBsAg positive patients, including Selleckchem AZD9291 124 (41%) HBeAg-positive samples, were tested for quantitative HBsAg levels (Abbott Architect) and HBV DNA (Cobas Taqman). In addition, HBcrAg was determined using the Lumipulse® G HBcrAg assay (Fujirebio), which measures HBeAg, HBcAg and the precore protein p22cr (aa28-150). Results: HBcrAg tested positive in 167 out of the 302 patients including all 124 HBeAg-positive and 43 out of 178 HBeAg-negative samples. A very robust Demeclocycline linearity of HBcrAg levels for up to 4 log dilutions was observed across HBV genotypes A, B, C and D. There was no significant difference in detection limits between HBV genotypes. HBcrAg showed a very high correlation with HBV DNA (Spearman correlation: r=0.88; linear regression r2=0.84;

p<0.0001) and a modest correlation with HBsAg levels (r=0.78; r2=0.47; p<0.0001). Correlation with HBV DNA was independent from HBV genotype A and D, and was also not influenced by HBeAg status. Conclusions: The HBcrAg assay shows a high accuracy across HBV genotypes A, B, C and D. Thus it can also be used in patients with HBV genotypes A and D. The clinical utility of HBcrAg testing to individualize management of patients with chronic HBV should be evaluated in further studies. Disclosures: Benjamin Maasoumy-Advisory Committees or Review Panels: Abbott Molecular; Speaking and Teaching: MSD, Roche Diagnostics, Roche Pharma Jerzy Jaroszewicz – Speaking and Teaching: Roche, Gilead, Abbott, MSD, BMS Michael P.